Business:
AAV capsid Gene Therapy
Drug notes:
13+ additional undisclosed programs RD ALS, Friedreich's ataxia, Parkinson's, rare neurological disease, CNS diseases, undisclosed
About:
Voyager Therapeutics is advancing delivery modalities for gene therapies. Many gene therapies are in development, yet delivery of the therapy is still a major limitation. AAVs are a popular choice but require high doses and have off-target effects. Voyager is using its TRACER screening platform to enhance AAV capsids’ specificity and ability to target desired cells and tissues. Voyager’s AAVs also pass the blood-brain barrier, offering the potential to cure neurological diseases. Initial non-human primate data demonstrate the selectivity of TRACER-derived capsids to target the CNS and cardiac muscle. These capsids may enable single-dose treatment for a broad spectrum of diseases.
Director/Senior Director, Corporate Counsel Lexington, MA|10 days ago
Senior Scientist, Oligonucleotide Chemistry Lexington, MA|16 days ago
Senior Scientist, Bioconjugation Lexington, MA|23 days ago